Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT04520659

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Conditions: RSV Infection

Sex: All

Ages: 6 Months – 24 Months

Healthy volunteers: Yes

Phase: PHASE1

Enrollment: 81

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Location: John Hopkins Bloomberg School of Public Health Baltimore Maryland

Summary

The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of a single dose of a recombinant, live-attenuated respiratory syncytial virus (RSV) vaccine, LID/ΔM2-2/1030s, in RSV-seronegative infants and children 6 to 24 months of age.

Eligibility Criteria

Inclusion Criteria: * ≥ 6 months of age and \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04520659). StuddyBuddy aggregates publicly available trial information.